Obesity treatment should focus on better health, not weight loss alone

• A new statement from The Endocrine Society says that obesity treatment success should include improvements in heart, metabolic, liver, sleep, mental, and physical health, not just the number on the scale.
• Newer drugs, such as semaglutide and tirzepatide, can support weight loss and may improve obesity-related conditions, but researchers still need to understand their long-term effects and optimal use.
• Due to possible complications from stopping treatment, researchers are exploring whether lower doses or alternative medications can help maintain benefits.
• The organization adds that more research is necessary, and has highlighted 6 major areas of research to focus on.

Obesity is a long-term health condition that can increase the risk of type 2 diabetes, hypertension, coronary heart disease, stroke, and certain cancers.

Estimates suggest that more than 40% of adults in the United States live with obesity. However, expanded obesity definitions, which include waist measurements and fat distribution, raise U.S. adult obesity rates to nearly 70%.

Typically, the main goal of obesity treatment is to achieve and maintain a healthy, sustainable weight. However, a new scientific statement from the Endocrine Society argues that the success of obesity treatment should not be measured by weight loss alone.

Instead, researchers and clinicians should focus increasingly on whether treatment improves overall health, reduces obesity-related complications, and helps people maintain those benefits over the long term.

The statement, published in The Endocrine Society’s journal, Endocrine Reviews, highlights major advances in obesity research, including the emergence of highly effective medications such as semaglutide and tirzepatide.

At the same time, it identifies important unanswered questions about how obesity develops, how people respond differently to treatment, and how safe and effective newer medications are when used for many years.